drugset / Trial / NCT02892344

Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

NCT02892344

Phase 3 Completed 802 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d. delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms of lung function and symptom control in poorly (ie inadequately) controlled asthma patients. This study was to assess contribution of LABA as an add-on therapy to low dose ICS monotherapy.

Timeline

Start
2017-01-16
Primary completion
2018-11-05
Completion
2018-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 150 ug
Subject Mometasone furoate Other / unclassified 80 ug
Subject Mometasone furoate Other / unclassified 200 ug

Indications